Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Restructurings -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (73)	2/4/2003 7:10:52 AM
From: Icebrg	Read Replies (1) \| Respond to of 270

CEGE 8 % (sort of). Cell Genesys Increases Cancer Product Focus and Eliminates Broad-Based Gene Therapy Research Tuesday February 4, 7:01 am ET FOSTER CITY, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE - News) today announced its decision to decrease further resource investment in broad-based gene therapy programs in order to increase the focus on the company's clinical programs focused on cancer vaccines and oncolytic virus therapies. In addition to the company's six clinical stage programs, Cell Genesys will continue to invest in its preclinical cancer product pipeline. Cell Genesys will no longer pursue its preclinical in vivo gene therapy programs including hemophilia and other genetic deficiency diseases and will discontinue further investment in gene therapy technology development. Twenty-six positions in Cell Genesys' 330-person workforce will be eliminated by this program management decision. Approximately one third of the affected employees will be transferred to other open positions within the company. Cell Genesys will continue to provide access to relevant gene therapy technologies to its majority-owned subsidiary, Ceregene, Inc., which is focused on gene therapies for neurologic disorders. "Cell Genesys has always been a company that has made active portfolio management decisions. While we remain in a strong financial position and are able to pursue multiple clinical programs in parallel, we believe it is best for our business and our shareholders to apply our resources to more advanced programs that we feel have the greatest chance for commercial success," stated Joseph J. Vallner, Ph.D., president and chief operating officer. "While it is difficult to say good-bye to employees, we have emerged from this program management decision with an even greater business focus in the development of cancer therapeutic products." Cell Genesys is focused on the development and commercialization of innovative biological therapies for cancer. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and cancer gene therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical programs of oncolytic virus therapies include CG7870 for prostate cancer. Preclinical studies are in progress for additional GVAX® cancer vaccines, oncolytic virus therapies and cancer gene therapies for multiple types of cancer. Cell Genesys' majority-owned subsidiary, Ceregene, Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold approximately 8.7 million shares of common stock in its former subsidiary, Abgenix, Inc., an antibody products company. Cell Genesys is headquartered in Foster City, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the c